Navigation Links
CEL-SCI Corporation Releases Letter to Shareholders
Date:2/20/2009

ale following approval. We have also designed the facility to be used as a contract manufacturing facility during those times (e.g., during certain times in the Phase III study) when we will not be producing Multikine. This lucrative business could quickly become a multi-million dollar revenue generator for CEL-SCI.

  • We presented very promising data on a new rheumatoid arthritis vaccine discovered by CEL-SCI scientists. The data presented was as good as that achieved with Enbrel, a leading treatment for rheumatoid arthritis.

  • We started planning and pricing our global clinical trial designed to lead to marketing approval for Multikine. The recent strength of the dollar will reduce our Phase III study costs by several million dollars.

While we are pleased by these accomplishments, we also recognize that there are major challenges due to the severe financial downturn. This downturn has affected all of us, but we have taken immediate action. We very quickly reduced our expenditures and expanded our discussions with various pharmaceutical companies for a world-wide Multikine partnership. Things are very difficult all around for most companies, but we are seeing new strength in the bigger biotechnology names. This will hopefully trickle down to the smaller ones like us as well. The huge buyouts in the industry, Pfizer buying Wyeth and Roche trying to buy Genentech, will add over $100 billion in liquidity to the industry, and that too should help us down the road.

Let me share with you how we at CEL-SCI are dealing with and planning for recovery from this financial downturn. In our opinion, during such a difficult time as this you cannot rely on one strategy alone. Therefore we are pursuing the following multi-pronged strategy. To
'/>"/>

SOURCE CEL-SCI Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine
2. CEL-SCI Enters Agreement With National Institutes of Health Clinical Center To Determine the Molecular Basis of Multikine Anti-Tumor Effect
3. CEL-SCI Expects to Take Delivery of New Manufacturing Facility on October 8, 2008
4. Data Suggest CEL-SCIs CEL-2000 Vaccine Prevents or Retards Permanent Damage of Rheumatoid Arthritis
5. CEL-SCI Corporation Reports First Quarter Financial Results
6. CEL-SCI Corporation Announces 2007 Financial Results
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
8. CEL-SCI to Present at Rodman & Renshaw 9th Annual Healthcare Conference
9. CEL-SCI CEO to Present at the International Society for Pharmaceutical Engineering 2007 Chesapeake BioShowcase
10. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
11. CEL-SCI CEO to Present Tomorrow at the Biotech / Pharma / Healthcare On-Line Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... , Aug. 27, 2015  Zimmer Biomet Holdings, ... musculoskeletal healthcare, announced that it will be participating in ... at the Goldman Sachs offices in London ... About the Company Founded in 1927 and headquartered in ... a global leader in musculoskeletal healthcare.  We design, manufacture ...
(Date:8/27/2015)... , Aug. 27, 2015  CytomX Therapeutics, ... the treatment of cancer, today announced that ... the company,s Board of Directors, has been appointed ... at Eli Lilly and AstraZeneca, and also oversaw ... approved checkpoint inhibitor, at Bristol-Myers Squibb and the ...
(Date:8/27/2015)... , Aug. 27, 2015  QB3@953—a ... a University of California (UC) research institute and ... company GSK to identify and facilitate collaborations to ... benefit patients. The agreement formalizes a ... Academia (DPAc) team and creates a new channel ...
Breaking Medicine Technology:Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 2Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer 3QB3@953 Signs Collaboration Agreement with GSK to Identify Early-Stage Drug Discovery Opportunities 2
... Top-Line Data Expected in the Third Quarter --, ... VIAP ), a biotechnology company focused on the development ... that,it has completed the last patient visit in its ... be analyzed to determine,VIA-2291,s effect on inflammation, and the ...
... Modigene,s CTP Technology for Extending ... of Action of Therapeutic Proteins -, NES-ZIONA, Israel, ... noted the successful completion of a Phase,III clinical trial ... uses the naturally occurring CTP,peptide to extend the duration ...
Cached Medicine Technology:VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 2VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 3VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 4VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial 5Modigene Platform Validated in Independent Phase III Trial of CTP Technology 2Modigene Platform Validated in Independent Phase III Trial of CTP Technology 3
(Date:8/27/2015)... ... August 27, 2015 , ... According to an article published ... released new guidelines to educate doctors and patients on the best practices for type ... came in 2007, so the new version is taking into account nearly a decade ...
(Date:8/27/2015)... Riverside, CA (PRWEB) , ... August 27, 2015 ... ... its plans to enter the exploding legal marijuana industry with the launch of ... adult consumers of legal marijuana to order products from their smart phones and ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... The Naderi ... now be offering Kybella, a cutting-edge, noninvasive procedure to improve submental fat. The ... Kybella provides permanent results without surgery. Dr. Kulak is the only Board Certified ...
(Date:8/27/2015)... FL (PRWEB) , ... August 27, 2015 , ... ... announce its partnership with Julia Glushko, professional Tennis player for Israel in the ... uses Zensah® Compression for all her training and recovery. , With a focus ...
(Date:8/27/2015)... ... August 27, 2015 , ... ... and leading biopharmaceutical contract development manufacturing company (CDMO), announced today that it has ... for $205.68M in cash. , The addition of Cytovance Biologics to ...
Breaking Medicine News(10 mins):Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 2Health News:Article on New Diabetic Care Guidelines Shines Brightly on Weight Loss Surgery, notes Beverly Hills Physicians 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 2Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 3Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 4Health News:Doobster Launches a Nationwide, Comprehensive On-Demand Medical Marijuana App 5Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 2Health News:Noninvasive Double Chin Elimination Now Available in Herndon and Chevy Chase 3Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 2Health News:Zensah® Compression Announces Partnership with WTA Tennis Professional Athlete, Julia Glushko 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4
... in Spanish . , Researchers of the ... University of Granada (Spain) have discovered that extra virgin ... a paper published in the last issue of the renowned ... the bioactivity of polyphenols (this is, natural antioxidants) present in ...
... Patient Care launches fourth-year program that focuses on ... Feb. 5 /PRNewswire/ -- The Partnership ... effort led by southeastern Pennsylvania hospitals and one ... Blue Cross, announces its new initiatives for 2009-2011 ...
... It,s In Our Hands - Has Been Designed ... and Caregivers to Healthcare Resources and Services in ... the initiation of its Community Health Partnership (CHP), ... Bronx area, seeking to link Hispanic residents with ...
... /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc.,(OTC Bulletin Board: ... developer, manufacturer and distributor in the People,s ... controlled subsidiary Beijing,Liang Fang Pharmaceutical Co., Ltd. ... million) in December 2008 for land use ...
... MinuteClinic, the pioneer and largest provider of ... that it has become a participating provider in ... South Carolina.BlueCross, Preferred Blue and Medicare Advantage members ... centers located in the Columbia and Greenville markets. ...
... 5 Palomar Medical Technologies, Inc. (Nasdaq: ... systems for cosmetic treatments, today announced financial results for ... Revenues for the quarter ended December 31, 2008 ... revenues, $2.2 million were royalty revenues, $0.5 million were ...
Cached Medicine News:Health News:Spanish scientists confirm extra virgin olive oil helps to combat breast cancer 2Health News:Region's Hospitals Engage in New Patient-Safety Efforts to Further Reduce Infections, Errors, and Improve Quality of Care 2Health News:Region's Hospitals Engage in New Patient-Safety Efforts to Further Reduce Infections, Errors, and Improve Quality of Care 3Health News:Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care 2Health News:Sanofi-aventis Partners with the Hispanic Community in Bronx to Increase Health Awareness, Access to Resources and Help Improve Patient Care 3Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 2Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 3Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 4Health News:Lotus Pharmaceuticals, Inc. Purchases Land Use Rights to Grow its Business and Reduce Costs 5Health News:MinuteClinic Becomes Participating Provider With Preferred Blue Network of BlueCross BlueShield of South Carolina 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 2Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 3Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 4Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 5Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 6Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 7Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 8Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 9Health News:Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2008 10
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: